Firma WELDING, Autor bei News-Research

WELDING Group Publishes First Standardized Sustainability Report

6. November 2026 Firma WELDINGPosted in AllgemeinTagged carbon, concrete, ecovadis, fiscal, future, gas, measures, media, report, Resource, safety, schumann, sustainability, welding, with

WELDING GmbH & Co. KG is proud to present its first standardized sustainability report for the 2025/26 fiscal year, developed in collaboration with neqon. The report is publicly available on […]

WELDING PHARMA API and CHEMISCHE FABRIK BERG Announce Exclusive Partnership for Lisdexamfetamine

29. September 2026 Firma WELDINGPosted in AllgemeinTagged API manufacturing, CHEMISCHE FABRIK BERG, CPhI Milan 2026, drug development, global pharmaceutical market, GMP-compliant, lisdexamfetamine, Lisdexamfetamine dimesilate, Market Access, pharmaceutical APIs, pharmaceutical partnership, Regulatory Compliance, supply chain, therapeutic innovation, WELDING PHARMA API

WELDING PHARMA API is proud to announce an exclusive partnership with CHEMISCHE FABRIK BERG for the development, manufacture and commercialization of Lisdexamfetamine dimesilate. Building on more than two decades of […]

Deepening Technical Expertise in Pet Food

8. September 2026 Firma WELDINGPosted in ProduktionstechnikTagged digestibility, extrusion, feedstock, gelling agents, high quality, microencapsulation, nutraceuticals, palatability, pet food, reliable, sensoryanalysis, shelf-life, stabilizers, technical expertise, training session

WELDING FEED, part of the WELDING Group, is deepening its collaboration with WELDING FOOD and its partner Eurogum – Bang & Bonsomer. By combining feed and food expertise, the partners […]

Quinine 200 mg Film-Coated Tablets (DCP Start)

2. September 202620. Oktober 2026 Firma WELDINGPosted in AllgemeinTagged 200 mg, antimalarial, biosimilar, commercialization, dcp, Decentralized Procedure, Film-Coated Tablets, generic medicines, medicinal formulation, pharmacovigilance, product licensing, Quinine, quinoline, regulatory approval, supply chain

Quinine 200 mg Film-Coated Tablets (DCP Start) The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of […]

WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

29. Mai 2026 Firma WELDINGPosted in AllgemeinTagged biosimilar development, Decentralized Procedure, drug registration, EMA approval, generic medication, international pharma market, market authorization, marketing authorizations, multi country generic approval, pharmaceutical licensing, regulatory expertise, regulatory pathway, supply resilience, Tafamidis 61 mg soft capsules, value-based partnerships

WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in […]

WELDING GmbH & Co. KG Expands to Latin America

27. Mai 2026 Firma WELDINGPosted in FirmeninternTagged Active Pharmaceutical Ingredients, competitive pricing, distribution expertise, Food Additives, functional nutrition, ingredient sourcing, international subsidiary, Latin American market, manufacturing standards, market expansion, méxico, pharmaceutical distribution, Regulatory Compliance, Supply Chain Resilience, traceability systems

WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening […]

Revio Therapeutics and Welding Group Announce Strategic Co-Development and Licensing Agreement for Innovative Specialty Oncology Product

24. März 202624. März 2026 Firma WELDINGPosted in AllgemeinTagged Biotechnology, cancer, drug development, healthcare innovation, Market Access, oncology, partnership, patient care, Regulatory Compliance, Revio, specialty pharmaceuticals, therapeutics

Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form […]